BioToxTech Co

BioToxTech Co Cash Flow per Share

The Operating Cash Flow per Share of BioToxTech Co (086040.KQ) as of Oct 17, 2026 is 456.60 KRW. In the previous year, Operating Cash Flow per Share was -489.90 KRW — a change of -193.20% (higher).

Cash Flow per Share

456.60KRW

YoY

-193.20%

Last updated:

Operating Cash Flow per Share of BioToxTech Co is 2025 456.60 KRW. Operating Cash Flow per Share of BioToxTech Co was 2024 -489.90 KRW. It decreases by -193.20% higher compared to the previous year.

The BioToxTech Co Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2018
210.62 KRW
Jan 1, 2019
99.34 KRW
Jan 1, 2020
314.00 KRW
Jan 1, 2021
299.04 KRW
Jan 1, 2022
-90.07 KRW
Jan 1, 2023
-1,117.27 KRW
Jan 1, 2024
-489.90 KRW
Jan 1, 2025
456.60 KRW
The BioToxTech Co Cash Flow per Share history
YEARCash Flow per ShareYoY
456.60KRW-193.20%
-489.90KRW-56.15%
-1,117.27KRW+1,140.41%
-90.07KRW-130.12%
299.04KRW-4.77%
314.00KRW+216.08%
99.34KRW-52.83%
210.62KRW-49.39%
416.17KRW+14.49%
363.51KRW-761.92%
-54.92KRW-61.02%
-140.88KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BioToxTech Co Stock analysis

What does BioToxTech Co do? BioToxTech Co Ltd, listed on the Korea Exchange under ticker 086040.KQ, is a South Korean company operating in the Health Care sector, specifically within Life Sciences Tools & Services. Headquartered in Cheongju, Chungcheongbuk-do, the company provides non-clinical drug trial services. It conducts safety evaluation research, including general and local toxicity tests, reproductive and developmental tests, genotoxicity assessments, immunotoxicity evaluations, carcinogenicity studies, safety pharmacology tests, ecotoxicology examinations, histopathology analyses, and hematology tests. The firm also offers efficacy evaluation research for medical supplies, health supplements, and cosmetics. Additionally, BioToxTech provides analysis research services such as pharmacokinetics (PK) and toxicokinetics (TK) testing, along with validation and bioanalysis services. The company went public on September 21, 2007, and acquired a 60% stake in a newly established subsidiary on March 13, 2013. Its website is https://www.biotoxtech.com/. BioToxTech focuses on supporting pharmaceutical and biotechnology industries through comprehensive preclinical research services, ensuring product safety and efficacy before clinical trials. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Operating Cash Flow per Share of BioToxTech Co is 456.60 KRW in 2025.

Operating Cash Flow per Share of BioToxTech Co changed from -489.90 KRW to 456.60 KRW, representing a -193.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — BioToxTech Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — BioToxTech Co